E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and/or Y |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammation of the brain and infection of the blood |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028911 |
E.1.2 | Term | Neisseria meningitidis infection NOS |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10070124 |
E.1.2 | Term | Neisseria meningitidis test positive |
E.1.2 | System Organ Class | 100000004848 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
One month after vaccination:
• To evaluate the non-inferiority of the vaccine response induced by the MenACWY TT conjugate vaccine when compared to the licensed Mencevax ACWY.
• To evaluate the non-inferiority of the MenACWY-TT conjugate vaccine when compared to the licensed Mencevax ACWY in terms of the incidence of any grade 3 systemic symptom within 4 days after vaccination one month after vaccination.
|
|
E.2.2 | Secondary objectives of the trial |
One month after vaccination:
• To compare the immunogenicity of MenACWY-TT conjugate vaccine with that of the licensed Mencevax ACWY
• To evaluate the reactogenicity of the MenACWY-TT conjugate vaccine when compared to the licensed Mencevax ACWY
Up to six months after vaccination:
• To describe serious adverse events (SAEs) and specific adverse events (onset of chronic illness(es), rash, and conditions prompting emergency room visits or physician office visits that are not related to well-being care, vaccination, injury, or common acute illnesses. This also included any event related to lack of vaccine efficacy)
One year, two years, three years, four years and five years after vaccination:
• To compare the persistence of the immunogenicity of MenACWY-TT conjugate vaccine with that of the licensed Mencevax ACWY
• To describe SAEs related to vaccination and any event related to lack of vaccine efficacy from 6 months up to five years after vaccination in a retrospective manner |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Subjects who the investigator believes that they and/or their parents/legally acceptable representative (LAR) can and will comply with the requirements of the protocol.
• A male or female between, and including, 11 and 55 years of age at the time of vaccination.
• Written informed consent obtained from the subject/ from the parent or LAR of the subject.
• Free of obvious health problems as established by medical history and clinical examination before entering into the study.
• Previously completed routine childhood vaccinations to the best of his/her knowledge and/or his/her parents’/LARs’ knowledge.
• If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilised or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, and must agree to continue such precautions for two months after completion of the vaccination series. Female subjects in childbearing potential who are not abstinent must have a negative pregnancy test. |
|
E.4 | Principal exclusion criteria |
• Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.
• Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine(s).
• Previous vaccination with meningococcal polysaccharide (PS) vaccine of serogroup A, C W and/or Y within the last five previous years.
• Previous vaccination with meningococcal PS conjugate vaccine of serogroup A, C W and/or Y.
• History of meningococcal disease due to serogroup A, C, W or Y.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.
• A family history of congenital or hereditary immunodeficiency.
• History of allergic disease or reactions likely to be exac-erbated by any component of the vaccine.
• Major congenital defects or serious chronic illness.
• History of any neurologic disorders or seizures.
• History of Guillain-Barré syndrome.
• Acute disease at the time of enrolment.
• Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
• Pregnant or lactating female.
• History of chronic alcohol consumption and/or drug abuse.
• Female planning to become pregnant or planning to discontinue contraceptive precautions.
Specific criteria to be checked at each study visit for the long term follow-up:
• History of meningococcal serogroup A,C, W and Y disease.
• Administration of a meningococcal PS or a meningococcal PS conjugate vaccine not planned in the protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Vaccine response to meningococcal antigens
• Occurrence of any grade 3 systemic symptoms |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
• One month post vaccination
• During the 4-day follow-up period after vaccination |
|
E.5.2 | Secondary end point(s) |
• Meningococcal rSBA titres
• Anti-meningococcal polysaccharide antibody concentrations
• Anti-tetanus toxoid seroprotection and antibody concentrations
• Occurrence of solicited local and general symptoms
• Occurrence of unsolicited symptoms
• Occurrence of serious adverse events (including meningococcal diseases)
• Occurrence of specific adverse events of rash, new onset of chronic illness(es) and conditions prompting emergency room visits and physician office visits not related to common illnesses
• Occurrence of serious adverse events (including meningococcal diseases) related to vaccination and any event related to lack of vaccine efficacy |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Prior to, 1 month and 1, 2, 3, 4 & 5 years after vaccination
• Prior to, 1 month and 1, 2 and 3 years after vaccination
• Prior to and 1 month after vaccination
• During the 4-day follow-up period after vaccination
• Up to 1 month after vaccination
• Up to 6 months after vaccination
• Up to 6 months after vaccination
• From 6 months up to 5 years after vaccination |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity, reactogenicity |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |